An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
for Stomatitis
20 locations incl. Tucson
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT07357597·Phase 4·Not Yet Recruiting